ALPL and hypophosphatasia: What’s more, the enzyme replacement therapy asfotase alfa (StrensiqTM; Alexion Pharmaceuticals Inc, New Haven, CT, USA), a recombinant human TNSALP, showed remarkable curative effect such as improvements in skeletal manifestation, pulmonary function, and growth in perinatal or infantile form HPP patients [29].